AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy The post Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma appeared first on Bio Tech Winners.
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
The American College of Cardiology (ACC), the American Heart Association, and nine other leading medical associations today released an updated guideline for the treatment of...
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they develop into tumors. The use of a...
The pharmaceutical company Grünenthal has begun the first Phase I study with its own orally available inhibitor of the voltage-gated sodium channel NaV1.8. The first healthy volunteers have already been enrolled...
